About
History
Major Events
2022年
3月
Community
Signed a comprehensive collaboration agreement with Kyoto Research Park
Exchange events and sharing of know-how.
Community
Signed a memorandum of understanding for strategic partnership with Suzhou Industrial Park, a science park in China
Promote alliances between resident companies, support for companies setting up operations in the two countries, and provide financing support, with the aim of promoting technological development and capital tie-ups in the biopharmaceutical industry in Japan and China.
5月
Initiatives
Implemented the second incubation program (Japan Innovation Bloom GRANT CALL 2022) with corporate sponsorship
Co-sponsored by Johnson & Johnson Innovation, Janssen Research & Development LLC. and Takeda Pharmaceutical Company Limited
9月
Initiatives
100 resident companies/organizations and 50 member companies/organizations
Continuous increase in tenants and members even during the COVID-19 pandemic
10月
Initiatives
The third phase of the "Japan VC Consortium" begins.
Theme "Biotech on the Leading Edge of Platform Technology"
11月
Initiatives
Held public event "Healthcare MaaS opens up the future of local communities"
Attracted a total of 1,400 visitors, mainly local residents.
2021年
2月
Initiatives
Launched the third "iPark Crowdfunding" project
Achieved more than 10 million yen for "Eliminating the Delay of Cancer - Early Detection of All Cancers Through Blood Diagnosis" project, nearly doubling the initial target amount.
4月
Community
Signed a memorandum of understanding for a partnership agreement with the National Horizons Centre (NHC), a science park in the U.K.
Conducted online exchange events.
7月
Initiatives
Launched the second phase of the Japan VC Consortium.
Twenty-five companies participated in the program under the themes of "Utilization of Bioinformatics at the Forefront" and "Biotech That has Realized the New Chemical Space".
Initiatives
An auditorium was opened free of charge to the city of Fujisawa as a regional vaccination site for the coronavirus vaccine
In cooperation with Shonan Kamakura General Hospital, a total of 9,000 people were vaccinated in the first and second rounds of vaccination.
8月
Management
IIF acquired 100% of the trust beneficiary rights to the land and facilities of Shonan iPark.
Shonan iPark continued to be operated by Takeda Pharmaceutical Company Limited under a trust agreement.
*Trust beneficiary right: The right to receive economic benefits arising from an asset.
Initiatives
Started purchasing 100% renewable energy electricity
Reduced greenhouse gas emissions from the facility by approximately 52.4% per year
11月
Initiatives
"Healthcare MaaS" demonstration experiment open to the public
Conducted an automated driving demonstration experiment to build a seamless mobility system jointly with Shonan Kamakura General Hospital, Mitsubishi Corporation, Mitsubishi Electric Corporation, and Macnica.
2020年
1月
Initiatives
The first corporate-sponsored incubation program ("World Without Disease call-for-proposals") is implemented.
Johnson & Johnson Innovation, Janssen Research & Development LLC., and Takeda Pharmaceutical Company Limited jointly sponsored a mentoring-oriented, long-term companion program.
3月
Initiatives
COVID-19 pandemic begins
Established the Shonan iPark COVID-19 Response Committee to continuously deliberate and implement a safe operating system, while also establishing a new and improved infrastructure for online and hybrid interactions
Initiatives
Formed a business alliance with READYFOR and launched "iPark Crowdfunding" to support research by venture companies and academia.
First project "Cancer Treatment with Less Side Effects by Developing Technology to Carry Drugs to Mitochondria!" achieved more than 10 million yen, 1.5 times the target amount.
4月
Management
Grounds are leased free of charge to Kanagawa Prefecture for the construction of temporary medical facilities for patients infected with COVID-19
Shonan Kamakura General Hospital operates the facility, accepting patients with moderate disease (closed at the end of the term in September 2022).
6月
Management
Takeda Pharmaceutical Company Limited and Mitsubishi Corporation UBS Realty (MCUBS) agreed to a comprehensive collaboration regarding the operation of Shonan iPark.
Shonan iPark’s assets (land and facilities) are placed into trust and Industrial & Infrastructure Fund Investment (IIFF) acquires trust beneficiary rights.
7月
Initiatives
Launch of the first phase of the Japan VC Consortium
Established to bring together VC, CVC, and the pharmaceutical investment sector to address issues in the Japanese life science investment market.
8月
Initiatives
General Incorporated Association iD4 established
Established to realize a stable supply system of iPS cells in Japan and to promote their industrial use.
9月
Initiatives
Launched the second "iPark Crowdfunding" project
The theme was "Liquid Liver, Bringing Enjoyment of Food to Phenylketonuria Patients!", and achieved more than 12 million yen in support, nearly double the initial target amount.
10月
Initiatives
Launched the third phase of the Shonan Conference, a consortium for solving social issues (perinatal depression).
Eight companies participated with Janssen Pharma as the sole sponsor.
2019年
2月
Initiatives
Launched the first phase of the Shonan Conference, a consortium for solving social issues (Mibyou).
Launched the Shonan Conference, a consortium of private companies from different fields aiming to solve social issues
5月
Community
Membership system begins
Aiming for a more diverse ecosystem, a membership system was started in which members do not have their own offices or laboratories, but only participate in the community.
Community
Kanagawa Prefecture, Fujisawa City, Kamakura City, Shonan Kamakura General Hospital, and Shonan iPark sign a memorandum of understanding for collaboration ("5 parties collaboration")
The parties agreed to collaborate and cooperate in the formation of a cutting-edge health innovation center in the Muraoka and Fukasawa areas.
7月
Initiatives
The second phase of the Shonan Conference, a consortium for solving social issues, begins (dementia).
Three business models were devised to create a society in which patients with dementia coexist.
Community
Signed a memorandum of cooperation with National Biotechnology Research Park (NBRP), a science park in Taiwan
Continuously hold joint events and tours
8月
Community
The number of resident companies and organizations exceeds 50
The ecosystem becomes more multidisciplinary and diverse with the addition of pharmaceutical companies other than Takeda and next-generation medical research companies.
2018年
4月
Management
Grand Opening of Shonan Health Innovation Park
Takeda Pharmaceutical Company Limited opens its Shonan Research Center to companies and universities, creating Japan's first science park initiated by a pharmaceutical company.
7月
Initiatives
First "Science Class for Parents and Children" is held
Researchers from the iPark resident companies serve as lecturers for parents and children at neighborhood elementary school.
8月
Initiatives
A portion of the site is opened to the public on weekends
As the first step toward opening the Science Park to the community, the lawn area was opened to the public
(later suspended due to typhoon damage and COVID-19).
10月
Initiatives
"MAP for the Practical Application of Regenerative Medicine" is published
Issues and recommendations for the realization of social implementation of regenerative cell medicine in Japan are compiled and published jointly with Kanagawa Prefecture.
Management
Announced Shonan iPark Mid-term Strategy
Announced growth plans for focus disease areas and ecosystem
Number of tenants and
member companies (organizations)
TENANTS & MEMBERS
- Tenants
- Members
